000			02034 a2200589 4500
005			20250517042659.0
264		0	_c20151006
008			201510s 0 0 eng d
022			_a1097-6787
024	7		_a10.1016/j.jaad.2015.04.041 _2doi
040			_aNLM _beng _cNLM
100	1		_aBatalla, Ana
245	0	0	_aCardiovascular risk factors influence response to biological therapies in psoriasis. _h[electronic resource]
260			_bJournal of the American Academy of Dermatology _cAug 2015
300			_a327-9 p. _bdigital
500			_aPublication Type: Comparative Study; Letter; Observational Study
650	0	4	_aAdalimumab
650	0	4	_aAdult
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aBiological Therapy _xadverse effects
650	0	4	_aCardiovascular Diseases _xdiagnosis
650	0	4	_aComorbidity
650	0	4	_aCross-Sectional Studies
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEtanercept
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xadministration & dosage
650	0	4	_aInfliximab
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPsoriasis _xdiagnosis
650	0	4	_aReceptors, Tumor Necrosis Factor _xadministration & dosage
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Factors
650	0	4	_aSeverity of Illness Index
650	0	4	_aSpain
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aUstekinumab
700	1		_aGonzález-Fernández, Daniel
700	1		_aGonzález-Lara, Leire
700	1		_aAbalde, Teresa
700	1		_aSalgado-Boquete, Laura
700	1		_aQueiro-Silva, Rubén
700	1		_aCoto, Eliecer
700	1		_aCoto-Segura, Pablo
773	0		_tJournal of the American Academy of Dermatology _gvol. 73 _gno. 2 _gp. 327-9
856	4	0	_uhttps://doi.org/10.1016/j.jaad.2015.04.041 _zAvailable from publisher's website
999			_c25083109 _d25083109